DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Silver Spring MD 20993

NDA 21112/S-9

SUPPLEMENT APPROVAL

Galderma Laboratories, LP
Attention: Richard Almond
Senior Manager, Regulatory Affairs
14501 North Freeway
Fort Worth, TX 76177

Dear Mr. Almond:

Please refer to your Supplemental New Drug Application (sNDA) dated June 20, 2013, received June 21, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tri-Luma® (fluocinolone acetonide, hydroquinone, tretinoin) Cream, 0.01%/4%/0.05%.

We acknowledge receipt of your amendments dated September 9, December 17 and 18, 2013; January 7, 13 and 17, and February 10, 2014.

This “Prior Approval” sNDA provides for revision of the Tri-Luma® (fluocinolone acetonide, hydroquinone, tretinoin) Cream, 0.01%/4%/0.05% full prescribing information to comply with the new labeling content and format requirements for human prescription drug and biological products, according to 21 CFR 201.56(d) and 201.57.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions listed below and included in the enclosed labeling.

- In Highlights under Warnings and Precautions, the cross-reference at the end of the second bullet should read “(5.2)”.
- In the Full Prescribing Information, the cross-references in section 1.2 and 5.1 should be written in sentence case, not in all caps, as follows:
  o [see Use in Specific Populations (8.1, 8.3)]
  o [see Warnings and Precautions (5.4)]

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to, including the above edits, the enclosed labeling (text for the package insert, text for the patient package insert) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 21112/S-9.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.
Because none of these criteria apply to your application, you are exempt from this requirement.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Paul Phillips, Regulatory Project Manager, at (301) 796-3935.

Sincerely,

{See appended electronic signature page}

Susan J. Walker, MD, FAAD
Director
Division of Dermatology and Dental Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURES:
   Content of Labeling
   Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUSAN J WALKER
03/31/2014